OSR Health Inc(OSRH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 3:45 PM ET (Korea 11/3 05:45)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.4 | Insider Own | 44.7% | Shs Outstand | 35.1M | Perf Week | -60.5% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 19.4M | Perf Month | -75.42% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | - | Inst Own | 1.89% | Short Float | 6.29% | Perf Quarter | -74.67% |
| Income | -0.01B | P/S | 2.26 | EPS this Y | - | Inst Trans | 12.67% | Short Ratio | 0.12 | Perf Half Y | -72.26% |
| Sales | 0.00B | P/B | 0.04 | EPS next 5Y | - | ROA | -6.1% | Short Interest | 1.22M | Perf YTD | -79.35% |
| Book/sh | 2.97 | P/C | 2.73 | EPS past 3/5Y | -518.53% -214.49% | ROE | -11.42% | 52W High | -88.35% ($1.00) | Perf Year | -88.47% |
| Cash/sh | 0.04 | P/FCF | - | Sales past 3/5Y | - | ROIC | -10.26% | 52W Low | 40.87% ($0.08) | Perf 3Y | -98.88% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 79.59% | Gross Margin | -488.28% | Volatility(W/M) | 63.66% 36.5% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 15.85 | Sales Y/Y TTM | -4.64% | Oper. Margin | -933.75% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.14 | EPS Q/Q | -244.91% | Profit Margin | -593.22% | RSI (14) | 32.56 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.18 | Sales Q/Q | -72.2% | SMA20 | -69.33% ($0.39) | Beta | 0.35 | Target Price | $10 |
| Payout | - | Debt/Eq | 0.05 | Earnings | - | SMA50 | -69.21% ($0.39) | Rel Volume | 0 | Prev Close | $0.12 |
| Employees | 22 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -77.26% ($0.53) | Avg Volume(3M) | 9.88M | Price | $0.12 |
| IPO | 2023/3/17 | Option/Short | No/Yes | Trades | 0 | Volume | - | Change | - |
🏥 OSR Holdings (OSRH) is a global healthcare holding company that went public on Nasdaq in 2025 through a SPAC merger. Through its subsidiaries, it simultaneously operates in immuno-oncology, regenerative medicine biologics, and medical device distribution. Its portfolio includes VXM01 (Vaximm), an oral T-cell immunotherapy targeting glioblastoma; Darnatein, a bone and cartilage regenerative biologic drug candidate; and RMC, a neurovascular medical device distribution business in Korea.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
OSRH has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $226. Peers typically go for $946. It is about in line with its own 2-year average.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -98.9%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #551 of 598 in the industry
Based on market cap of $4M.
FAQ
What kind of company is OSRH?
OSRH belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OSRH?
The market cap of OSRH is approximately $4M, ranking 5,772 within its sector.
What is the 52-week high and low for OSRH?
OSRH has recorded a 52-week high of $1.00 and a low of $0.08.
